Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country
ICIs appear safe in patients with chronic hepatitis B, especially when antiviral treatment is given. We believe these patients should not be deprived of the potential benefits of ICIs solely because of chronic viral infection, neither in daily practice nor in clinical trials.
Authors
- Abdurrahman Işıkdoğan (ORCID: https://orcid.org/0000-0002-7451-7286)
- Onur Yazdan Balçık (ORCID: https://orcid.org/0000-0002-3386-2075)
- Zafer Arık (ORCID: https://orcid.org/0000-0002-0598-389X)
- Taha Koray Şahin (ORCID: https://orcid.org/0000-0002-3590-0426)
- Mert Tokatlı (ORCID: https://orcid.org/0000-0003-4914-7903)
- Leyla Sert
- Mustafa Erman (ORCID: https://orcid.org/0000-0001-5884-4669)
- Onur Baş (ORCID: https://orcid.org/0000-0002-8726-0360)
- Gözde Kavgacı (ORCID: https://orcid.org/0000-0001-6960-2024)
- Nur Evşan Boyraz
- Deniz Can Güven (ORCID: https://orcid.org/0000-0002-6924-9467)
Institutions
- Dicle University (TR)
- Mardin Artuklu University (TR)
- State Hospital (GB)
- Hacettepe University (TR)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1080/14737140.2025.2529290
- Citations
- 1
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35